🏢 公司Newsroom01099Doubao · 实盘不做把握 8/10不做原因:无增量信息
北京时间·🕒 发布 18:24:02·⟳ 抓取 18:24:27回填·⚡ 决策 10-19 18:38:30·8.4 天前
国药控股（01099.HK）公告将于2026年10月23日召开董事会审议三季度业绩
这是港交所规则下的例行董事会会议通知，只告知将于10月23日开会审议三季报，未包含任何收入、利润、指引、分红或商业事件信息，对股价没有方向性增量；周末港股已闭市，亦无可即时交易的 edge。三季报本身（10月23日）才是潜在催化，届时应另行研判。
📄 原文01099↗ 原文
Announcements and Notices - NOTICE OF BOARD MEETING pdf
Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the con…
不做 国药控股 Sinopharm Group Co. Ltd.（01099.HK）
仅为例行董事会会议通知（10月23日审议三季报），无任何业绩数字、指引或商业增量，方向不明、无 edge；周末港股闭市无法成交，且三季报本身才是独立催化，不应据此通知提前布局。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
国药控股仅发布董事会会议通知，预告10月23日审议三季度业绩，无任何业绩数字或新增事实；属程序性日历事件，无方向、无 edge，不做。
🔎 新鲜度:最早出现 2026-10-19 · 扩散 low · price-in 风险 low ↗
主要风险
- 10月23日正式三季报若大幅超/低于预期，才会产生方向性波动，但那是另一独立事件，不能用本条会议通知提前押注。
先例如何影响了这次决策
对本次决策的影响:确认本条不产生交易；不据此设定任何 tp/sl，等待业绩公告另行研判。
方向:无可参照先例；董事会会议通知本身不含增量信息，不具备用历史事件校准方向或幅度的基础。
涨幅量级:无业绩数字或商业条款，无法也无需校准涨跌幅。
形态:例行会议日期通知通常无价格反应；真正的反应窗口在10月23日业绩公告当日。
工具执行结果 · 成功 1 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 14 ms
{"result": "search_processed_events:agent query=`sinopharm group 01099 board meeting notice quarterly results 30 september 2026 | sinopharm 国药控股 董事会会议通知 2026年10月23日 三季度业绩`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 0.0/72 小时、0 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agent query 表达式没有召回候选，不能据此证明消息首发或不是重复；按当前事件继续正常研判。"}
原文全文
展开原文 · 2,068 字
Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no
responsibility for the contents of this notice, make no representation as to its accuracy or
completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or
in reliance upon the whole or any part of the contents of this notice.
SINOPHARM GROUP CO. LTD.*
(A joint stock limited company incorporated in the People’s Republic of China with limited
liability and carrying on business in Hong Kong as 國控股份有限公司)
(Stock Code: 01099)
NOTICE OF BOARD MEETING
The board of directors (the “Board”) of Sinopharm Group Co. Ltd. (the “Company”) hereby
announces that a meeting of the Board will be held on Friday, 23 October 2026, for the purpose of
considering and approving, among other matters, the unaudited quarterly results of the Company
and its subsidiaries for the three months ended 30 September 2026.
By order of the Board
Sinopharm Group Co. Ltd.
Jin Bin
Chairman
Shanghai, the PRC
19 October 2026
As at the date of this notice, the executive Directors are Mr. Lian Wanyong and Mr. Yang Binghua;
the non-executive Directors are Mr. Jin Bin, Mr. Chen Qiyu, Mr. Zu Jing, Mr. Xing Yonggang, Mr.
Ma Yue, Mr. Chen Yuqing, Mr. Wen Deyong and Ms. Li Ying; and the independent non-executive
Directors are Mr. Li Peiyu, Mr. Wu Tak Lung, Mr. Yu Weifeng, Mr. Shi Shenghao and Mr. Chen
Weiru.
* The Company is registered as a non-Hong Kong company under the Hong Kong Companies
Ordinance under its Chinese name and the English name “Sinopharm Group Co. Ltd.”.
1
responsibility for the contents of this notice, make no representation as to its accuracy or
completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or
in reliance upon the whole or any part of the contents of this notice.
SINOPHARM GROUP CO. LTD.*
(A joint stock limited company incorporated in the People’s Republic of China with limited
liability and carrying on business in Hong Kong as 國控股份有限公司)
(Stock Code: 01099)
NOTICE OF BOARD MEETING
The board of directors (the “Board”) of Sinopharm Group Co. Ltd. (the “Company”) hereby
announces that a meeting of the Board will be held on Friday, 23 October 2026, for the purpose of
considering and approving, among other matters, the unaudited quarterly results of the Company
and its subsidiaries for the three months ended 30 September 2026.
By order of the Board
Sinopharm Group Co. Ltd.
Jin Bin
Chairman
Shanghai, the PRC
19 October 2026
As at the date of this notice, the executive Directors are Mr. Lian Wanyong and Mr. Yang Binghua;
the non-executive Directors are Mr. Jin Bin, Mr. Chen Qiyu, Mr. Zu Jing, Mr. Xing Yonggang, Mr.
Ma Yue, Mr. Chen Yuqing, Mr. Wen Deyong and Ms. Li Ying; and the independent non-executive
Directors are Mr. Li Peiyu, Mr. Wu Tak Lung, Mr. Yu Weifeng, Mr. Shi Shenghao and Mr. Chen
Weiru.
* The Company is registered as a non-Hong Kong company under the Hong Kong Companies
Ordinance under its Chinese name and the English name “Sinopharm Group Co. Ltd.”.
1
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
b34ef747db· 2026-10-19 18:38 · doubao / doubao-seed-evolving-latest-version · 策略包658c0c1e2ba5当前